Cd24fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect

HIGHLIGHTS

  • who: Mingyue Liu from the (UNIVERSITY) have published the paper: CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect, in the Journal: (JOURNAL) of 13/02/2022
  • future: Studies are needed to fully elucidate the mechanism of action by CD24Fc.

SUMMARY

    As the first step to understand how CD24Fc reduces Treg in tumor microenvironment, the authors tested if CD24Fc affect Treg differentiation in the presence of TGFβ and other inflammatory cytokines. As shown in Supplementary Fig 6, CD24Fc did not affect Tregs differentiation in_vitro in the presence of . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?